All In Biotech

Drug Trial Radar · NCT02598661

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 289 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

289

Actual

Start

Jan 12, 2016

Primary completion

Oct 13, 2023

Study completion Oct 13, 2026

Sponsor

Lead sponsor
Geron CorporationIndustry
Sponsor type
Industry
First posted
Nov 6, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of imetelstat sodium in transfusion-dependent participants with low or intermediate-1 risk myelodysplastic syndrome (MDS) that is relapsed/refractory to erythropoiesis-stimulating agent (ESA) treatment in Phase 2 study and to compare the efficacy, in terms of red blood cell (RBC) transfusion independence (TI), of imetelstat sodium to placebo in transfusion-dependent participants with low or intermediate-1 risk MDS that is relapsed/refractory to ESA treatment in Phase 3 study. A separate Ventricular Repolarization Substudy (QTc Substudy) will evaluate the effect of imetelstat sodium on ventricular repolarization. An Extension Phase has been included to allow continued treatment for those participants who are benefitting from imetelstat sodium and to continue to evaluate the long-term safety, overall survival (OS), and disease progression, including progression to acute myeloid leukemia (AML) in transfusion-dependent participants with low or immediate-1 risk MDS that is relapsed/refractory to ESA treatment.

Conditions

  • Myelodysplastic Syndromes

Interventions

  • Imetelstat SodiumDrug

    Imetelstat sodium IV infusion.

  • PlaceboDrug

    Imetelstat sodium-matching placebo IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2: Percentage of Participants Without Any Red Blood Cell (RBC) Transfusion During Any Consecutive 8-Weeks Period (All Participants)Time frame: Up to 5 years in Phase 2
  2. Phase 2: Percentage of Participants Without Any RBC Transfusion During Any Consecutive 8-Weeks Period in Target PopulationTime frame: Up to 5 years in Phase 2
  3. Phase 3: Percentage of Participants Without Any RBC Transfusion During Any Consecutive 8-Weeks PeriodTime frame: Up to 3.7 years in Phase 3

Locations

126 sites in 17 countries. Site status is shown where the registry gives one.

  • UAB Comprehensive Cancer Center

    Birmingham, Alabama

  • Acrc/Arizona Clinical Research, Inc.

    Tucson, Arizona

  • CBCC Global Research, Inc.

    Bakersfield, California

  • UCLA Ronald Regan Medical Center

    Los Angeles, California

  • Yale-New Haven Hospital (YNHH) - Smilow Cancer Hospital

    New Haven, Connecticut

  • BRCR Medical Center

    Plantation, Florida

  • University of South Florida (USF) - H. Lee Moffitt Cancer Center

    Tampa, Florida

  • Franciscan Health

    Indianapolis, Indiana

  • St. Agnes Healthcare, Inc

    Baltimore, Maryland

  • Center for Cancer and Blood Disorders

    Bethesda, Maryland

  • Washington University School of Medicine

    St Louis, Missouri

  • University of New Mexico Cancer Center

    Albuquerque, New Mexico

  • Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • Weill Cornell Medical College-New York Presbyterian Hospital

    New York, New York

  • Cleveland Clinic Taussig Cancer

    Cleveland, Ohio

  • The Ohio State Comprehensive Cancer Center

    Columbus, Ohio

  • Prairie lakes Healthcare system, Inc

    Watertown, South Dakota

  • Vanderbilt University Medical - Hematology-Oncology

    Nashville, Tennessee

  • Texas Oncology/Methodist Charlton Cancer Center

    Dallas, Texas

  • Simmons Comprehensive Cancer Center

    Dallas, Texas

  • Fred Hutchinson Cancer Research Center (FHCRC)

    Seattle, Washington

  • AZ Klina

    Brasschaat, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • UZ Leuven - Campus Gasthuisberg

    Leuven, Belgium

  • ZAS Middelheim

    Antwerp, Antwerpen, Belgium

  • ZAS Cadix

    Antwerp, Antwerpen, Belgium

  • GZA Ziekenhuizen - Campus Sint

    Wilrijk, Antwerpen, Belgium

  • AZ Sint-Jan Burgge-Oostende

    Bruges, West-Vlaanderen, Belgium

  • Az Groeninge

    Kortrijk, West-Vlaanderen, Belgium

  • Tom Baker Cancer Centre

    Calgary, Alberta, Canada

  • University of Alberta Hospital - Hematology Research

    Edmonton, Alberta, Canada

  • The Ottawa Hospital

    Ottawa, Ontario, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • FN Kralovske Vinohrady

    Prague, Czechia

  • Vseobecna fakultni nemocnice v Praze

    Prague, Czechia

  • Fakultni nemocnice Brno

    Brno, Brno-město, Czechia

  • FN Hradec Kralove

    Hradec Králové, Hradec Králové, Czechia

Showing 40 of 126 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.